A randomised phase IV study to compare two rates of dosage tapering, when switching patients to aripiprazole from other atypical antipsychotics for the treatment of schizophrenia and schizoaffective disorder.

Trial Profile

A randomised phase IV study to compare two rates of dosage tapering, when switching patients to aripiprazole from other atypical antipsychotics for the treatment of schizophrenia and schizoaffective disorder.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top